Ionis Pharmaceuticals, Inc. (IONS)
NASDAQ: IONS · Real-Time Price · USD
82.70
0.00 (0.00%)
Nov 26, 2025, 4:00 PM EST - Market closed
Ionis Pharmaceuticals Employees
Ionis Pharmaceuticals had 1,069 employees as of December 31, 2024. The number of employees increased by 142 or 15.32% compared to the previous year.
Employees
1,069
Change (1Y)
142
Growth (1Y)
15.32%
Revenue / Employee
$904,543
Profits / Employee
-$239,796
Market Cap
13.40B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1,069 | 142 | 15.32% |
| Dec 31, 2023 | 927 | 131 | 16.46% |
| Dec 31, 2022 | 796 | 136 | 20.61% |
| Dec 31, 2021 | 660 | -97 | -12.81% |
| Dec 31, 2020 | 757 | -60 | -7.34% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IONS News
- 9 days ago - Ionis Pharmaceuticals, Inc. (IONS) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 13 days ago - Biogen Completes Acquisition of Alcyone Therapeutics - GlobeNewsWire
- 14 days ago - DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE) - Business Wire
- 14 days ago - Ionis Pharmaceuticals, Inc. (IONS) Presents at Stifel 2025 Healthcare Conference Transcript - Seeking Alpha
- 15 days ago - Ionis Prices Convertible Notes Offering to Refinance 2026 Convertible Notes - Business Wire
- 15 days ago - Ionis to present at upcoming investor conferences - Business Wire
- 16 days ago - Ionis Announces Proposed Convertible Offering to Refinance 2026 Convertible Notes - Business Wire
- 17 days ago - Ionis Pharmaceuticals, Inc. (IONS) Discusses Detailed Phase III Results for Olezarsen in Severe Hypertriglyceridemia Transcript - Seeking Alpha